ENTRY       D11528                      Drug
NAME        Viltolarsen (JAN/USAN);
            Viltepso (TN)
PRODUCT     VILTEPSO (NS Pharma)
FORMULA     C244H381N113O88P20
EXACT_MASS  6921.3564
MOL_WEIGHT  6924.8155
REMARK      Therapeutic category: 1900
            ATC code: M09AX12
            Product: D11528<JP/US>
EFFICACY    Translation inhibitor
  DISEASE   Duchenne muscular dystrophy (amenable to exon 53 skipping mutated) [DS:H01963]
  TYPE      Antisense oligonucleotide
COMMENT     Treatment of Duchenne muscular dystrophy
TARGET      DMD* [HSA_VAR:1756v1] [HSA:1756] [KO:K10366] (pre-mRNA exon53)
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             M MUSCULO-SKELETAL SYSTEM
              M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
               M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
                M09AX Other drugs for disorders of the musculo-skeletal system
                 M09AX12 Viltolarsen
                  D11528  Viltolarsen (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
              Viltolarsen
               D11528  Viltolarsen (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              19  Other agents affecting nervous system and sensory organs
               190  Other agents affecting nervous system and sensory organs
                1900  Other agents affecting nervous system and sensory organs
                 D11528  Viltolarsen (JAN/USAN)
            Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Cellular process
               Cytoskeleton
                DMD* [HSA_VAR:1756v1]
                 D11528  Viltolarsen (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11528
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11528
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11528
            Pharmacogenomic biomarkers [br08341.html]
             Germline mutations in genetic disorder treatments
              D11528
DBLINKS     CAS: 2055732-84-6
            PubChem: 384585504
///
